Dr. Daniel L. Murman, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Nebraska College of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 392
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: University of Nebraska College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NE license 22874
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Nebraska Medical Center Omaha, NE
- Bellevue Medical Center Bellevue, NE
Medical groups
- Unmc Physicians (1,518 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 392
- Services billed
- 769
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 294 | 163 |
| Established patient office or other outpatient visit, 40-54 minutes | 289 | 270 |
| New patient office or other outpatient visit, 60-74 minutes | 124 | 124 |
| Established patient office or other outpatient visit, 30-39 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Omaha, NE | 741 |
| Memantine Hcl Other prescribers in Omaha, NE | 675 |
| Sertraline Hcl Other prescribers in Omaha, NE | 362 |
| Galantamine Er (galantamine hbr) Other prescribers in Omaha, NE | 178 |
| Escitalopram Oxalate Other prescribers in Omaha, NE | 174 |
| Trazodone Hcl Other prescribers in Omaha, NE | 167 |
| Mirtazapine Other prescribers in Omaha, NE | 106 |
| Memantine Hcl Er (memantine hcl) Other prescribers in Omaha, NE | 88 |
| Fluoxetine Hcl Other prescribers in Omaha, NE | 57 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Omaha, NE | 54 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $80.00 in total to this clinician.
| F. Hoffmann-la Roche AG | $80.00 |
|---|
| Food and Beverage | $80.00 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $134,797 in research payments for these studies, mostly to the institutions running them.
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT06653153 - A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease
Biogen, Inc. - PostGraduate Roll Over Study
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.